Heavy files landed nationwide!

The financial verification crisis of 77 pharmaceutical companies that lasted for 2 years has just passed, and the punishment of revoking the product listing because of commercial bribery has been convicted of serious dishonesty.

On April 12, the Zhejiang Pharmaceutical Equipment Procurement Platform issued the "Notice on the Evaluation Results of Medical Prices and Untrustworthy Levels of Recruitment and Procurement in Our Province (2021 Phase One)".

The notice shows that it is based on the "Guiding Opinions of the National Medical Security Administration on Medicine Price and Recruitment Credit Evaluation System.

The Lugua Polypeptide Injection of Harbin Yuheng Pharmaceutical Co.

According to the judgment notified by Zhejiang Province, since 2017, the defendant Ni Dongmin has contracted drug promotion business in Zhejiang from pharmaceutical companies such as Harbin Yuheng Pharmaceutical Co.

From May 2017 to June 26, 2019, after defendant Lu Gang obtained the promotion fee for Lugua polypeptide injection from Harbin Yuheng Pharmaceutical Co.

It is reported that Zhejiang Province has also carried out credit evaluations in accordance with procedures for other pharmaceutical companies with rebate problems, and some pharmaceutical companies have taken measures such as proactive price reductions to restore credit.

In fact, as early as August 2020, the National Medical Insurance Agency launched the construction of a medical price and credit evaluation system, and gave rebates to outstanding issues in the medical field, played a guiding and standardizing role in the centralized procurement of medical products, and promoted the return of reasonable prices of medical products.

This time, Zhejiang Province notified the credit evaluation results of a certain company's Lugua Polypeptide Injection and suspended online transactions.

To a certain extent, it is not difficult to see that the country’s recent determination to rectify the pharmaceutical industry has been very clear.